Clinical trial
Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study
NCT04132557 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 9, 2019
- Completion date
- October 25, 2019
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.